The Only Cholesterol Sentence FDA Wrote Out for You

which cholesterol sentence did fda declare appropriate?

FDA declared exactly one cholesterol structure/function claim appropriate, and it wrote the sentence itself: 'helps to maintain cholesterol levels that are already within the normal range.' The wording comes from the preamble to the agency's 2000 structure/function final rule, the regulation — still in force — that separates a lawful supplement claim from an unapproved new drug claim. Nothing shorter passes, because the qualifier about the normal range is not decoration; it is the mechanism that keeps the sentence out of disease territory.

FDA wrote this sentence itself — advertisers never had to guess at it.

FDA's reasoning starts from a premise most cholesterol copy never engages. FDA wrote that "elevated blood pressure (hypertension) and elevated cholesterol (hypercholesterolemia) are diseases themselves, with subsequent events (heart attack, stroke) the late consequences of those diseases," in the same 2000 final rule. That single line is why this vertical has a lower ceiling than most operators assume: addressing the number on a lipid panel is addressing a disease, not a risk factor for one.

why did fda reject 'maintains healthy cholesterol'?

FDA rejected 'maintains healthy cholesterol' because the word 'healthy' had already been claimed by a different meaning in the same aisle. FDA explained that "the phrase 'healthy cholesterol' is now frequently used to refer to high density lipoproteins (HDL)," HDL being the lipoprotein people call good cholesterol. A claim meant to describe a normal total-cholesterol reading lands, on your customer, as a claim about raising HDL instead, which is a different and unsubstantiated promise sitting inside a sentence that looked safe.

The confusion runs the other way, too. Marketers who write 'supports healthy cholesterol' usually mean total cholesterol, LDL, or both, and FDA's objection means the phrase invites the reader to hear HDL rather than the number the product is actually meant to touch.

FDA also applies a whole-page test, not a sentence-by-sentence one. The same rule states that the agency reviews all cholesterol claims to judge whether the labeling as a whole implies the product lowers elevated levels, so a lawful sentence paired with a before-and-after testimonial about dropping LDL still fails, no matter how careful the sentence itself was.

what work does 'already within the normal range' do legally?

The qualifier does the entire legal separation between a maintenance claim and a disease claim. It converts a statement about a number into a statement about staying at a number the body already has; drop the phrase and the same sentence reads as a promise to change an abnormal reading, which is drug territory. FDA wrote that "FDA continues to believe that 'lowers cholesterol,' however qualified, is an implied disease claim," and applied the same logic to euphemism, ruling that language like 'promotes cholesterol clearance' is equally disqualified because it is directed at lowering rather than at maintaining a range already normal.

FDA applies the identical grammar outside cholesterol. Structure/function claims survive only where the underlying condition is common and not seriously harmful — the same test that let FDA write presbyopia onto the list of aging changes ordinary enough for a structure/function claim, while never naming hearing loss at all in the same body of guidance. Cholesterol gets no such opening, because FDA classified hypercholesterolemia itself as a disease, so there is no 'age-related and common' escape hatch to write toward.

Hedging the sentence doesn't create a second lawful version. FDA's Small Entity Compliance Guide treats 'reduces cholesterol' as a symptom claim for cardiovascular disease in its own right, concluding that "any claim about them would be an implied disease claim," per FDA's compliance guide. We counted: the permitted sentence runs nine words longer than the phrase FDA rejected, and every one of those nine words is doing legal work, not marketing polish.

FTC ran a parallel example on hedged cholesterol claims, describing a company citing preliminary studies that suggested its product may reduce cholesterol. We could not verify FTC's exact concluding sentence in that example — the source copy we captured was truncated — so pull FTC's Health Products Compliance Guidance and read Example 13 in full before quoting FTC's own conclusion on hedge wording.

who is left in the audience once that qualifier is added?

The audience left after that qualifier is narrow, and it doesn't match the audience most cholesterol offers are built to reach. 'Helps to maintain cholesterol levels that are already within the normal range' is, by its own text, a claim aimed at someone whose lab work already came back normal and who wants to keep it that way — not someone whose doctor just flagged an LDL number, not someone searching for a way to bring a reading down, and not the reader most direct-response cholesterol creative is written for. That's an uncomfortable fact for anyone building a funnel around this claim: the sentence FDA wrote out is the only lawful one, and it was written for the customer with the least urgency to buy. Operators who run this niche honestly are, in effect, selling maintenance to people who don't yet know they need it, using the one sentence that legally can't promise the number will move.

We counted five same-day warning letters FDA sent to cholesterol-supplement sellers on November 14, 2022: iwi, BergaMet North America, Essential Elements, Chambers' Apothecary and Anabolic Laboratories, all charged 'New Drug/Misbranded' the same day. FDA's letter to BergaMet cited the product's own name, 'Cholesterol Command,' its guarantee promising results 'if they do not improve your LDL levels,' and Facebook replies the brand had liked as evidence the company was making a drug claim rather than a maintenance one.

If your landing page pairs the permitted sentence with a before-and-after testimonial about a dropped LDL score, you've reintroduced the disease claim FDA spent the sentence avoiding, and FDA's own labeling-as-a-whole test catches exactly that combination.

You can write the sentence correctly and still lose the case on the page around it.

does the same grammar apply to blood sugar and metabolic claims?

Yes, FDA wrote a parallel forbidden-and-permitted pair for blood sugar in the same rule, and the logic is identical to cholesterol's. It rejected 'use as part of your diet when taking insulin to help maintain a healthy blood sugar level' because pairing the claim with a named drug implies treating the disease that drug treats, but accepted the same sentence once the reference to insulin was deleted — the same maintenance-of-a-normal-state grammar, just with a drug name instead of an HDL confusion to strip out. We describe the exact wording FDA wrote out for blood sugar supplements on its own page, because the insulin trap catches a different mistake than the HDL one does.

The parallel breaks down at enforcement volume, not at grammar. FDA's own warning-letter database returns 105 letters mentioning 'cholesterol' against 100 for 'blood sugar' and 146 for 'diabetes,' counts that span every FDA-regulated product type, not supplements alone — treat them as a rough ranking rather than a supplement-specific tally, and check the current count before publishing a firmer number.

which authorized health claims exist in this area instead?

Five authorized health claims exist in this territory, and none of them is a cholesterol-lowering claim available to a pill. 21 CFR part 101 subpart E sets out risk-of-coronary-heart-disease claims tied to specific dietary substances, each carrying its own qualifying conditions on fat content, serving size or delivery form.

Every one of these requires FDA's significant scientific agreement standard, a higher evidentiary bar than the qualified-claim letters used elsewhere in supplement marketing, and every one attaches to a food substance a manufacturer must formulate around rather than to a supplement formula sold on its own merits.

why are those claims about diets rather than pills?

Those claims describe diets because the statute authorizing them was built for food substances tied to intake patterns, not for isolated ingredients sold as a capsule. The model language runs to phrases like 'may reduce the risk of CHD' attached to a pattern of eating — replacing saturated fat, adding soluble fiber, including soy protein or plant sterols — never to a single ingredient's effect on a lab number by itself.

The ceiling sits on the same short, closed list we track on the aging claims FDA put on the non-disease list: a fixed set of authorized health claims that hasn't grown to cover joint pain, vein health or sleep either, and that stands separately from the qualified health claim and FDAMA authoritative-statement routes, both of which remain closed for cholesterol-lowering pills specifically.

No pill gets there by writing better copy.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, You Still Have to Prove What You Only Implied, Occasional Sleeplessness Is the Word FDA Allows, 'Occasional' Is the Word Holding Up Energy Offers, The Calm Claims FDA Listed as Acceptable, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.